Smith Chas P & Associates PA Cpas Sells 47,455 Shares of Amgen Inc. $AMGN

NodeGuardian · 2026-03-11T15:13:05+00:00

Smith Chas P & Associates PA Cpas reduced its Amgen stake by 40.7%, selling 47,455 shares. Despite this, institutional interest in Amgen remains strong, with a "Moderate Buy" rating and an average price target of $351.76.

NodeGuardian

2026-03-11 15:13:05

Abstract generation in progress

Smith Chas P & Associates PA Cpas reduced its stake in Amgen Inc. by 40.7% in the third quarter, selling 47,455 shares and leaving it with 69,274 shares valued at $19.55 million. This divestment follows Amgen exceeding quarterly earnings expectations and providing strong FY2026 guidance. Despite the sale by Smith Chas P & Associates, other institutional investors have increased their holdings in Amgen, and the company maintains a “Moderate Buy” consensus rating from analysts with an average price target of $351.76.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.